logo
Man who credits King over cancer diagnosis given pioneering robotic microsurgery

Man who credits King over cancer diagnosis given pioneering robotic microsurgery

Independent10-02-2025

An avid golfer who dismissed signs of cancer as a mark from his golf bag has become the first patient in the UK to have robotic microsurgery.
Nick Lees, 47, from Godalming in Surrey, eventually sought help after seeing news articles surrounding the King's cancer diagnosis.
He then discovered that he had a rare type of skin cancer 'the size of two 50 pence pieces'.
Around the time King Charles was having his cancer treatments, there was a lot of coverage about it. I thought: 'Oh, OK, I better go to the doctor's
Nick Lees
Medics needed to urgently remove the cancer.
And to aid the reconstruction of the tissue and vessels which were damaged during the cancer-removal procedure, they used robotic-assisted microsurgery – the first time it has been used in the UK.
The robot can replicate the natural movements of the human hand at the micro-scale.
Experts at the Royal Marsden hospital in London hailed the success of the operation – saying how surprised they were that Mr Lees was able to return to work just weeks afterwards.
Mr Lees, an estate agent, told the PA news agency: 'I had a mark that had been on my chest for a while.
'It appeared, and it wasn't causing me any discomfort, so I got used to it.
'I kind of assumed that it was because I played golf regularly, I carry a golf bag, and the strapping and sort of caused this sort of marking.
'But around the time King Charles was having his cancer treatments, there was a lot of coverage about it.
'I thought: 'Oh, OK, I better go to the doctor's.'
'So, went to the GP, she didn't think it was anything, but said to get it checked out.
'So, I went to see this dermatologist, and they did a biopsy, and then they called me back in and said: 'Look, unfortunately, it's revealed you've got this sort of rare form of sort of skin cancer.'
'I was pretty taken aback, that was last thing I was expecting her to say.'
Mr Lees was diagnosed with dermatofibrosarcoma protuberans – a rare type of soft tissue sarcoma – in his chest.
Sarcoma is a type of cancer that develops in the body's connective tissues including fat, muscle, nerves and blood and lymph vessels.
Mr Lees was referred to the world-renowned cancer hospital where he was under the care of consultant surgeon, Professor Andrew Hays, and consultant plastic and reconstructive surgeon Aadil Khan.
The procedures took place in November last year and now Mr Lees has since been given the all-clear.
The Royal Marsden Cancer Charity funded a UK-first robotic-assisted microsurgery system, called Symani Surgical System.
We are now able to connect blood vessels of up to half a millimetre in diameter together very precisely and very kind of accurately using the robot.
Aadil Khan
Mr Khan told PA: 'The Symani system is the first open microsurgery robotic system that's been developed in the world, and we are the first hospital in the UK to have it.
'Traditionally, when we used to do microsurgery, we would look down a microscope and we would manually use stitches to connect blood vessels together in order to perform these microsurgical reconstructions for patients who are having cancer treatment.
'What the Symani system now does is that it has robotic arms which take over that connection of blood vessels.
'So the surgeon sits remotely from the patient, looking at a screen in the same way that other robotic surgery is performed, and I have controllers in my hand that allow me to control the arms of the robot.
'And so we are now able to connect blood vessels of up to half a millimetre in diameter together very precisely and very kind of accurately using the robot.
'The technology itself means that it kind of eliminates the tremor at when you're working at particularly very, very small levels, so your connections are much more precise and much more accurate.'
He went on: 'Because we have greater reliability around connecting blood vessels of a smaller calibre than we did before… it's better for the patient in terms of recovery, mobilisation and healing after surgery.'
Researchers at the hospital are now studying the effectiveness of the tool to see whether it could bring wider benefits to the NHS across the country.
Mr Lees added: 'I feel quite honoured that they asked me to be the first patient.
'Obviously, when the surgeon first mentioned it, I was not too sure, but then I went away and thought about it and just felt that I'm in safe hands, I have a good relationship with the surgeon and everything had been first class in terms of how I've been sort of looked after at the Royal Marsden, so I had complete confidence in them.
'I also felt that I could do something that might help them, and also then others that come after.'
Mr Khan added: 'For Nick, we were able to do a slightly less invasive procedure.
'And actually, when I saw him in clinic, he had gone back to work and that was quite significant, because I didn't think he would be back at work as soon as he had been, but within weeks after surgery, he was, he was back to his job.
'He's had a great result. He's had a great outcome. And he's cancer free.'
Mr Kieran Power, head of the plastic surgery unit and consultant plastic and reconstructive surgeon at The Royal Marsden, said: 'We are hugely excited by the potential of Symani and the possibilities it offers patients in terms of faster recovery, less pain and improving quality of life following surgery.'
Antonia Dalmahoy, managing director of the Royal Marsden Cancer Charity, said: 'We are delighted that the Charity's funding has made it possible for The Royal Marsden to pave the way in improving cancer treatment and care, for the benefit of patients right across the UK and around the world.'

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

NHS to receive £6bn to provide millions more tests and procedures, Reeves confirms
NHS to receive £6bn to provide millions more tests and procedures, Reeves confirms

The Independent

timean hour ago

  • The Independent

NHS to receive £6bn to provide millions more tests and procedures, Reeves confirms

Rachel Reeves has pledged a £6bn investment aimed at accelerating tests and treatments within the NHS, following substantial year-on-year budget increases for the health service. The additional funding will facilitate new scanners, ambulances, and urgent treatment centres, with the goal of delivering up to four million more tests and procedures over the next five years. This announcement follows the chancellor's emphasis on NHS funding in her recent spending review, where she allocated an additional £29bn annually to the NHS budget. However, this increase comes at the expense of other areas of public spending. The £6bn boost is intended to support the Government's objective of reducing NHS waiting lists in England, according to the chancellor. 'Over a decade of underinvestment from the previous government put the NHS on its knees, with people across the country unable to get the care they need. We are investing in Britain's renewal, and we will turn that around,' Ms Reeves said. She added: 'Part of our record investment will deliver four million tests, scans and procedures, so hard-working people can get the healthcare they and their families need. 'There is no strong economy without a strong NHS, and we'll deliver on our Plan for Change to end the hospital backlog, improve living standards and get more money in people's pockets.' The latest spending commitment will help patients get access to diagnostic scans and treatment in places such as shopping centres and high streets, speeding up their diagnoses. The Government hopes this will help to cut NHS waiting lists, meeting Labour's goal of ensuring the health service carries out 92 per cent of routine operations within 18 weeks. Health Secretary Wes Streeting said: 'Since taking office we have been relentless in our drive to cut waiting times for patients, delivering over 3.6 million extra elective care appointments and reducing the overall waiting list by over 200,000. 'The £6bn investment we are announcing today will generate millions more vital diagnostic tests, scans and procedures for patients across the country.' On Wednesday evening, Ms Reeves said the Government was 'confident' it could meet its pledge to reduce waiting lists after giving the NHS a 3 per cent annual increase in funding at the spending review. Some health leaders are, however, sceptical that the Government will meet its target, despite the funding boost provided at the spending review. Matthew Taylor, chief executive of the NHS Confederation, which represents all health organisations, warned 'difficult decisions will still need to be made as this additional £29bn won't be enough to cover the increasing cost of new treatments, with staff pay likely to account for a large proportion of it'. He added: 'So, on its own, this won't guarantee that waiting time targets are met.' Sarah Woolnough, chief executive of the King's Fund charity, said: 'The chancellor said she wants the public to have an NHS there when they need it. 'It is hard to see how all the things she mentions: faster ambulance times, more GP appointments, and adequate mental health services and more can be met on this settlement alone. 'Particularly when large parts of this additional funding will be absorbed by existing rising costs, such as the higher cost of medicines, which are currently being negotiated, and covering staff pay deals.'

UK Pharmaceutical industry at risk from government's 'sky-high' rebates system
UK Pharmaceutical industry at risk from government's 'sky-high' rebates system

Daily Mail​

timean hour ago

  • Daily Mail​

UK Pharmaceutical industry at risk from government's 'sky-high' rebates system

The UK's status as a leader in medical research is at risk from 'sky-high and unpredictable' repayments pharmaceutical firms hand the Government, says an industry boss. Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said the rebate system – where firms repay money they make through selling medicines to the NHS – was sending 'a terrible message to international investors'. Rachel Reeves promised to support 'the UK's strengths in life sciences' and 'ensure patients get rapid access to the most clinically and cost-effective new technologies'. The Treasury plans to invest up to £520million in drug manufacturing in the next five years. Another £600million is earmarked for a health data research service to accelerate the discovery of new medicines. But Torbett said more was needed. 'Over the past decade, accounting for inflation, the NHS budget has grown by a third in real terms, while investment in the most rigorously cost-benefit-tested part of health spending – investment in the medicines needed to treat people – has fallen from around 11 per cent to 9 per cent of the health budget,' he added. And he attacked plans to increase what drug companies must repay from drug sales to 31.3 per cent, from 15.5 per cent. 'The sky-high and unpredictable payment rates send a terrible message to international investors when the UK is trying to position life sciences research and development as an engine for health and growth. For the sake of patients, the NHS and the economy, we need a commitment to bring these unsustainable rates down.'

The Inkey List's glycolic acid exfoliating stick worked magic on my keratosis pilaris
The Inkey List's glycolic acid exfoliating stick worked magic on my keratosis pilaris

The Independent

time2 hours ago

  • The Independent

The Inkey List's glycolic acid exfoliating stick worked magic on my keratosis pilaris

If you struggle with keratosis pilaris (also known as strawberry skin – a build-up of keratin within our skin pores) or sore razor bumps, then listen up. The much loved-affordable skincare brand The Inkey List may have produced the answer to our collective grumbles. Having sold out after its original launch, this stick claims to reduce the appearance of keratosis pilaris, razor bumps, hyper-pigmentation, breakouts and ingrown hairs. Results are promised after just one week, and drastic improvements are said to be visible after a month of consistent use. How does this miracle product work? Well, it's a combination of skin-loving hero ingredients. The glycolic acid is used to exfoliate the skin's surface and remove dead cells that leave the skin feeling rough, bumpy and uneven in tone. Salicylic acid helps to unclog oily pores, which is what causes issues like breakouts and ingrown hairs. Finally, shea butter offers a hydrating and moisturising effect. Chemical exfoliants have become the way of the future, and after testing this product, I'm beginning to see why. Here's how I got on with this miracle stick. How I tested Using the exfoliating stick every night for the last two months, I targeted keratosis pilaris on my arm, as well as underarm razor bumps and dry heels and elbows. I followed instructions carefully, starting by only using the stick two or three times a week and building up to every night once my skin had gotten used to it. To assess the product's efficacy, I looked for two things, appearance and texture. I noted any decrease in redness and improvement in brightness and paid close attention to any changes in the dryness or bumpiness of my skin.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store